About CinCor
CinCor is a company based in Cincinnati (United States) founded in 2018 by Jon Isaacsohn was acquired by Astrazeneca in January 2023.. CinCor has raised $193 million across 2 funding rounds from investors including Astrazeneca, General Atlantic and CinRx Pharma. The company has 15 employees as of March 31, 2022. CinCor operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Cincinnati, United States
- Employees 15 as on 31 Mar, 2022
- Founders Jon Isaacsohn
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Cincor Pharma, Inc.
-
Annual Revenue
-
Net Profit
$-50.37 M-126as on Dec 31, 2021
-
EBITDA
$-42.51 M-101as on Dec 31, 2021
-
Total Equity Funding
$193 M (USD)
in 2 rounds
-
Latest Funding Round
$143 M (USD), Series B
Oct 12, 2021
-
Investors
Astrazeneca
& 14 more
-
Employee Count
15
as on Mar 31, 2022
-
Acquired by
Astrazeneca
(Jan 09, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Scientific Team
7 people
Leadership Team
3 people
Operations Team
2 people
CSO Team
1 people
Unlock access to complete
Funding Insights of CinCor
CinCor has successfully raised a total of $193M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $143 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $143.0M
-
First Round
First Round
(14 May 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Series B - CinCor | Valuation | General Atlantic | |
| May, 2019 | Amount | Series A - CinCor | Valuation | Sofinnova Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CinCor
CinCor has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, General Atlantic and CinRx Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CinCor
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CinCor
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cincor Comparisons
Competitors of CinCor
CinCor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cincor
Frequently Asked Questions about CinCor
When was CinCor founded?
CinCor was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is CinCor located?
CinCor is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Who is the current CEO of CinCor?
Jon Isaacsohn is the current CEO of CinCor. They have also founded this company.
Is CinCor a funded company?
CinCor is a funded company, having raised a total of $193M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on May 14, 2019.
How many employees does CinCor have?
As of Mar 31, 2022, the latest employee count at CinCor is 15.
What does CinCor do?
CinCor was founded in 2018 in Cincinnati, United States, within the biotechnology sector. Focus is placed on developing therapeutics for cardio-renal diseases. The lead candidate, CIN-170, functions as an aldosterone synthase inhibitor targeting the renin-angiotensin-aldosterone system. Applications include treatments for hypertension, kidney diseases, and associated conditions, with operations centered in the United States.
Who are the top competitors of CinCor?
CinCor's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Who are CinCor's investors?
CinCor has 15 investors. Key investors include Astrazeneca, General Atlantic, CinRx Pharma, RTW Investments, and Perceptive Advisors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.